News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Michael Van Ameringen, MD

Articles by Michael Van Ameringen, MD

ocd psychedelics cannabis

OCD, Psychedelics, and Cannabinoids: New Evidence

ByMichael Van Ameringen, MD,Jessica Walters

February 11th 2026

New research highlights psilocybin's potential in treating treatment-resistant OCD, while cannabinoids show little evidence of efficacy.

Latest Updated Articles

OCD, Psychedelics, and Cannabinoids: New Evidence
February 11th 2026

Trending on Psychiatric Times

Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder

FDA Issues CRL for Cytisinicline for Smoking Cessation in Adults

Evaluating Transdermal Asenapine in Schizophrenia

Empowering Patients and Expanding Formulation Options in Schizophrenia Care